Status:
UNKNOWN
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3
Lead Sponsor:
Hospital Clinic of Barcelona
Conditions:
HIV-1 Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Maraviroc is an antiretroviral drug that belongs to the family of the CCR5 coreceptor inhibitors. It has proven to be effective in increasing CD4 lymphocyte counts in both in treated and naïve patient...
Eligibility Criteria
Inclusion
- 18 years of age or older
- HIV infection
- Patients receiving HAART treatment for at least one year with a sustained viral load equal or below 200 copies/ml
- Viral load equal or below 200 copies/ml at the screening visit
- Discordant patients: patients without an increment over 50 copies /ml of CD4 lymphocytes during the last year
- Patients with an expected adherence to HIV treatment over 90% according to their physician.
- Signed informed consent form
Exclusion
- Pregnancy or breast feeding or women planning pregnancy during the study duration
- Any contraindication to treatment with Maraviroc
- X4 tropism at inclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01235013
Last Update
November 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínic i Provincial
Barcelona, Barcelona, Spain, 08036